2-amino-3',5'-dichlorobiphenyl | 859080-02-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-3',5'-dichlorobiphenyl
• 英文别名: 3,5-dichlorophenylaniline；3',5'-dichloro-biphenyl-2-ylamine；3'.5'-Dichlor-2-amino-diphenyl；3',5'-Dichlor-biphenyl-2-ylamin；ortho-(3,5-dichlorophenyl)aniline；3',5'-Dichloro-biphenyl-2-amine；2-(3,5-dichlorophenyl)aniline
• CAS: 859080-02-7
• 化学式: C₁₂H₉Cl₂N
• 分子量: 238.116
• InChiKey: OYTLRQNDXDWCCY-UHFFFAOYSA-N

物化性质

• 沸点：
  367.7±27.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-amino-3',5'-dichlorobiphenyl 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Hinkel; Hey, Journal of the Chemical Society, 1928, p. 2787,2789

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 tin(ll) chloride 作用下， 生成 2-amino-3',5'-dichlorobiphenyl
  参考文献：
  名称：

  Hinkel; Hey, Journal of the Chemical Society, 1928, p. 2787,2789

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Aryl and biaryl piperidines with MCH modulatory activity
  申请人：PHARMACOPEIA, INC.

  公开号：US20030013720A1

  公开（公告）日：2003-01-16

  In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown below: 1

  在一个实施例中，这项发明提供了一类新型化合物，作为MCH受体的拮抗剂，包括制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及治疗、预防或改善与MCH受体相关的一种或多种疾病的方法。下面展示了一个说明性的创新化合物： 1
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• Palladium-catalyzed primary amine-directed regioselective mono- and di-alkynylation of biaryl-2-amines
  作者：Guangbin Jiang、Weigao Hu、Jianxiao Li、Chuanle Zhu、Wanqing Wu、Huanfeng Jiang

  DOI：10.1039/c7cc09308j

  日期：——

  The first example of the palladium-catalyzed primary amine-directed C(sp2)–H alkynylation of biaryl-2-amines has been developed by using (bromoethynyl)triisopropylsilane as an alkynylating reagent. This protocol exhibits a broad substrate scope, excellent regioselectivity and gram-scale synthesis. Significantly, the versatility of this straightforward method was further demonstrated by controlled mono-

  通过使用（溴乙炔基）三异丙基硅烷作为烷基化试剂，开发了钯催化的伯芳基-2-胺的伯胺定向的C（sp 2）–H烷基化伯胺的第一个例子。该协议具有广泛的底物范围，出色的区域选择性和克级合成。值得注意的是，这种简单方法的多功能性通过受控的单和双炔基化进一步得到证明。